NewAmsterdam Pharma (NAMS) Cash from Investing Activities (2023 - 2026)

NewAmsterdam Pharma has disclosed Cash from Investing Activities across 4 years of filings, most recently posting -$11.5 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$11.5 million, down 503.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$189.3 million (down 217.54% YoY), and the FY2025 annual result was -$174.9 million, down 178.32% from the prior year.
• Cash from Investing Activities came in at -$11.5 million for Q1 2026 at NewAmsterdam Pharma, up from -$21.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $2.9 million in Q1 2025 to a low of -$159.1 million in Q2 2025.
• The 4-year median for Cash from Investing Activities is -$75000.0 (2024), against an average of -$19.2 million.
• Across the five-year window, Cash from Investing Activities slumped 2072533.33% in 2024 and soared 3441.33% in 2025, its largest moves.
• NewAmsterdam Pharma's Cash from Investing Activities stood at -$3000.0 in 2023, then plunged by 2072533.33% to -$62.2 million in 2024, then soared by 66.0% to -$21.1 million in 2025, then jumped by 45.56% to -$11.5 million in 2026.
• The last three Cash from Investing Activities figures came in at -$11.5 million (Q1 2026), -$21.1 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.